Public articles linked to the same research event.
Bioscience Reports This review systematically examines how DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA networks drive chemoresistance and recurrence in ovarian cancer, summarizes clinical trial results of epigenetic agents (DNMT, HDAC, and EZH2 inhibitors) combined with PARP inhibitors or immunotherapy, and reviews biomarker advances based on circulating cfDNA methylation, circulating miRNAs, and AI-based liquid biopsy platforms, proposing a precision oncology framework for patient stratification and real-time monitoring of chemoresistance.
This review systematically examines how DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA networks drive chemoresistance and recurrence in ovarian cancer, summarizes clinical trial results of epigenetic agents (DNMT, HDAC, and EZH2 inhibitors) combined with PARP inhibitors or immunotherapy, and reviews biomarker advances based on circulating cfDNA methylation, circulating miRNAs, and AI-based liquid biopsy platforms, proposing a precision oncology framework for patient stratification and real-time monitoring of chemoresistance.
This review systematically examines how DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA networks drive chemoresistance and recurrence in ovarian cancer, summarizes clinical trial results of epigenetic agents (DNMT, HDAC, and EZH2 inhibitors) combined with PARP inhibitors or immunotherapy, and reviews biomarker advances based on circulating cfDNA methylation, circulating miRNAs, and AI-based liquid biopsy platforms, proposing a precision oncology framework for patient stratification and real-time monitoring of chemoresistance.
This review systematically examines how DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA networks drive chemoresistance and recurrence in ovarian cancer, summarizes clinical trial results of epigenetic agents (DNMT, HDAC, and EZH2 inhibitors) combined with PARP inhibitors or immunotherapy, and reviews biomarker advances based on circulating cfDNA methylation, circulating miRNAs, and AI-based liquid biopsy platforms, proposing a precision oncology framework for patient stratification and real-time monitoring of chemoresistance.